ReviewCurrent hypertension reports2017
Lipidomics in the Study of Hypertension in Metabolic Syndrome.
Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A new perspective on special effective interventions for metabolic syndrome risk factors: a systematic review and meta-analysis.Frontiers in public health · 2023Pooled it
- Lipidomic signatures in Colombian adults with metabolic syndrome.Journal of diabetes and metabolic disorders · 2024Article
- Plasma lipidomic profiling reveals six candidate biomarkers for the prediction of incident stroke in patients with hypertension.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Gut microbiota: a potential new regulator of hypertension.Frontiers in cardiovascular medicine · 2024Review
- Epigenome-wide association study in Chinese monozygotic twins identifies DNA methylation loci associated with blood pressure.Clinical epigenetics · 2023Article
- Effects of ambient particulate exposure on blood lipid levels in hypertension inpatients.Frontiers in public health · 2023Article
- Effects of ozone exposure on lipid metabolism in Huh-7 human hepatoma cells.Frontiers in public health · 2023Article
- Joint interaction effect of metabolic syndrome and obstructive sleep apnea on hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe entire gamut of changes in the lipid profile that precede, predict, and correlate with hypertension in metabolic syndrome is unknown. RECENT
findingsThe power, resolution, and accuracy of lipidomic assay technologies have brought us to the threshold of another information explosion. Understanding of hypertension and its pathophysiology especially within the setting of metabolic syndrome has been greatly improved by recent lipidomic studies. Hypertension in metabolic syndrome differs from other forms of hypertension, and recent studies have highlighted this difference in many interesting ways. Mounting evidence points towards a derangement of the sphingolipid pathway that may trigger the precursor clinical conditions of hypertension as well as hypertension itself. In this review, we summarize the available published literature in this field and propose a unifying hypothesis based on the published evidence. Recent studies have created substantial interest and advances in the understanding of hypertension in metabolic syndrome. Studies that directly test these concepts within a lipidomic framework are urgently needed.
Indexed as
Identifiers
28168678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.